Mutation detail:
| Mutation site | E30Q |
| Virus | Human rhinovirus |
Mutation level  |
Amino acid level |
| Gene/protein/region type | P3-A |
| Gene ID | 1461213 |
| Country | - |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | B |
| Sample |
cell line |
| Variants | - |
| Viral reference sequence | NC_001490.1 |
| Drug/antibody/vaccine | Enviroxime resistant |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | 3A (P3-A) |
| Uniprot protein ID | P03303 |
| Protein length | 85 amino acids |
| Protein description | P3-A localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the disassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface. P3-A plays an essential role in viral RNA replication by recruiting ACBD3 and PI4KB at the viral replication sites, thereby allowing the formation of the rearranged membranous structures where viral replication takes place. |
Literature information:
| Pubmed ID | 7769678 |
| Clinical information | No |
| Disease | - |
| Published year | 1995 |
| Journal | Journal Of Virology |
| Title | The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus |
| Author | B A Heinz, L M Vance |
| Evidence | TABLE2 |